GLAXO WELLCOME SEREVENT WITH CORTICOSTEROIDS MAY SUBSTITUTE FOR A DOUBLE DOSE OF CORTICOSTEROIDS -- NHLBI GUIDELINES; CONTROL OF NOCTURNAL SYMPTOMS CITED
Executive Summary
Glaxo Wellcome's long-acting beta2-agonist Serevent is suitable for concomitant use with inhaled corticosteroids for the treatment of moderate persistent asthma, according to new asthma guidelines issued by the National Heart, Lung & Blood Institute. "Moderate persistent" asthma is a new category in the revised NHLBI guidelines.
You may also be interested in...
FDA Pediatric Drug Division Director Will Be GSK’s Shirley Murphy
Former GlaxoSmithKline NeuroHealth Specialty Division VP Shirley Murphy, MD, will become the first director of FDA's Division of Pediatric Drug Development effective Sept. 9
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011